Thebaine Urine Testing

NCT ID: NCT07192887

Last Updated: 2025-09-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-05-07

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To develop and validate a urine drug screen to detect thebaine.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urine Specimen Collection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female
* Ages 18-65
* Healthy

Exclusion Criteria

* Allergy to poppy seeds, or any of the related food stuffs used in the study
* Celiac disease or gluten sensitivity
* Ongoing or opioid use in the past 6 months
* History of renal or hepatic disease or dysfunction
* Inability or unwillingness to give repeated urine specimens
* Unwillingness to refrain from eating poppy seed-containing products during the two-day course of the study
* Non-English speakers (due to study materials being in English)
* BMI greater than 30
* Antibiotic use in the previous 2 months
* Recent ingestion of poppy seeds from the previous 7 days
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Children's Hospital Medical Center, Cincinnati

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Charlotte Walter, MD

Role: PRINCIPAL_INVESTIGATOR

Children's Hospital Medical Center, Cincinnati

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Charlotte Walter, MD

Role: CONTACT

513-636-4408

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Charlotte Walter, MD

Role: primary

513-636-4408

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-0818

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Response to Clenbuterol in Humans
NCT03860870 COMPLETED NA
Pharmacokinetics of Oral Thiamine
NCT01433952 COMPLETED PHASE1
Methemoglobin Concentration in High Dose Inhaled Nitric Oxide
NCT05612074 ACTIVE_NOT_RECRUITING EARLY_PHASE1
L-Citrulline and Endothelial Function
NCT05722860 RECRUITING PHASE1
Three Times Daily Dosing of UT-15C
NCT01746485 COMPLETED PHASE1
Expanded Access to Triheptanoin
NCT03773770 AVAILABLE